Core Viewpoint - SAILUN Biotech is actively developing multiple innovative biopharmaceuticals and snake venom rapid diagnostic test projects, which are currently in the research and development stage [2] Group 1 - The company has confirmed that aside from its already listed products, it is focusing on several innovative biopharmaceuticals and diagnostic tests [2] - The company encourages stakeholders to pay attention to its annual report and the annual "quality improvement and efficiency enhancement" action plan for insights into its business strategy and development plans [2]

（编辑 楚丽君） 证券日报网讯 1月14日，赛伦生物在互动平台回答投资者提问时表示，除日常学术推广活动外，公司配 合专业学会在多个省份开展蛇伤规范化救治培训与研讨会和"蛇伤防治科普基层行"等活动，提高医护蛇 伤救治知识和民众急救意识，同时，不断迭代"赛伦100蛇伤防治"小程序，通过多种方式提高科普知识 传播受众面。 ...

（记者 曾健辉） 每经头条（nbdtoutiao）——海利生物增值9倍并购的企业，估值8个月"腰斩"，其第一大客户竟是尚未 成立的公司，离奇的事还不少…… 每经AI快讯，*ST张股1月14日晚间发布业绩预告，预计2025年归属于上市公司股东的净利润亏损4.5亿 元~5.5亿元。基本每股收益亏损0.56元~0.68元。本报告期亏损主要原因是大庸古城预计计提资产减值， 计提资产减值最终金额须经公司聘请的评估机构及审计机构进行评估和审计后确定。 ...

Market Overview - The biopharmaceutical sector experienced a decline of 0.9% on January 14, with Rongchang Biopharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 4126.09, down 0.31%, while the Shenzhen Component Index closed at 14248.6, up 0.56% [1] Stock Performance - Notable gainers in the biopharmaceutical sector included: - Aidi Pharmaceutical, closing at 19.83 with a rise of 16.72% and a trading volume of 242,400 shares, totaling 462 million yuan [1] - Wufan Biopharmaceutical, closing at 57.38 with an increase of 4.35% and a trading volume of 47,900 shares, totaling 272 million yuan [1] - Kangbuno, closing at 71.99 with a rise of 4.17% and a trading volume of 49,300 shares, totaling 355 million yuan [1] - Rongchang Biopharmaceutical saw a significant decline, closing at 103.34 with a drop of 9.72% and a trading volume of 196,700 shares, totaling 2.091 billion yuan [2] Capital Flow - The biopharmaceutical sector experienced a net outflow of 656 million yuan from institutional investors, while retail investors saw a net inflow of 407 million yuan [2] - Notable capital flows included: - Watson Biopharmaceuticals with a net inflow of 63.73 million yuan from institutional investors [3] - Kanghua Biopharmaceuticals with a net inflow of 18.92 million yuan from institutional investors [3] - Overall, retail investors contributed a net inflow of 4.07 billion yuan to the sector [2]

2025年前三季度，智翔金泰实现营业收入2.08亿元，同比增长1,562.05%；实现归属于上市公司股 东的净利润-3.33亿元；实现归属于上市公司股东的扣除非经常性损益的净利润-3.70亿元；经营活动产 生的现金流量净额为-2.61亿元。 (责任编辑：田云绯) 智翔金泰首次公开发行股票募集资金总额347,283.84万元；扣除发行费用后，募集资金净额为 329,140.14万元。智翔金泰实际募资净额比原拟募集资金金额少68,859.86万元。智翔金泰于2023年6月15 日披露的招股说明书显示，该公司拟募集资金398,000.00万元，用于抗体产业化基地项目一期改扩建、 抗体产业化基地项目二期、抗体药物研发项目、补充流动资金。 智翔金泰首次公开发行股票的发行费用合计18,143.70万元（不含税），其中，保荐承销费16,495.98 万元。 智翔金泰已连亏4年3季。2021年至2024年，智翔金泰归属于上市公司股东的净利润分别为-3.22亿 元、-5.76亿元、-8.01亿元、-7.97亿元；归属于上市公司股东的扣非净利润分别为-3.34亿元、-6.45亿 元、-8.13亿元、-8.04亿元。 中国经济网北 ...

Core Viewpoint - Rongchang Biopharmaceutical (688331.SH) experienced a significant decline in stock price, closing at 103.34 yuan, down 9.72% [1] Group 1: Analyst Reports - Huatai Securities analysts Dai Wen, Yuan Zhongping, and Li Hang published a report on January 13, maintaining a WACC of 6.5% and a perpetual growth rate of 2.5%, adjusting the DCF-based target price for A-shares to 151.79 yuan (previously 140.42 yuan) [1] - The A/H premium was adjusted to 16.46%, consistent with the past three months' A/H premium for Rongchang Biopharmaceutical, up from the previous 8.95% [1] - The target price for H-shares was adjusted to 142.72 HKD (previously 141.13 HKD), with a "buy" rating maintained for both A-shares and H-shares [1] Group 2: Clinical Development and Product Pipeline - Huazhong Securities analysts Tan Guochao and Ren Wanying also published a report on January 13, expressing optimism about the clinical advancement of RC148, the progress of the company's pipeline, and the stable sales growth of its listed products, maintaining a "buy" rating [1]

Market Overview - On January 13, major indices in China experienced collective adjustments, with the Shenzhen Component Index falling over 1% and the ChiNext Index dropping nearly 2%. The Shanghai Composite Index closed down 0.64%, the Shenzhen Component Index down 1.37%, and the ChiNext Index down 1.96%. The total trading volume in the Shanghai and Shenzhen markets reached 3.65 trillion yuan, an increase of 49.6 billion yuan compared to the previous trading day [1] - In the U.S. stock market, the three major indices also declined on January 13. The Dow Jones Industrial Average fell by 398.21 points to close at 49,191.99, a decrease of 0.80%. The S&P 500 Index dropped by 13.53 points to 6,963.74, down 0.19%, while the Nasdaq Composite Index decreased by 24.03 points to 23,709.87, a decline of 0.10% [1] Sector Performance - In the Chinese market, over 3,700 stocks declined, with the AI application concept sector rising against the trend, seeing over ten constituent stocks hitting the daily limit up. The AI medical concept remained active, while the power grid equipment sector strengthened in the afternoon. The retail sector also showed active performance. Conversely, the commercial aerospace and controllable nuclear fusion sectors experienced significant declines [1] - In the U.S., the performance of major indices reflected a general downward trend, indicating a cautious market sentiment [1] Commodity Prices - International oil prices rose on January 13. The price of light crude oil futures for February delivery on the New York Mercantile Exchange increased by $1.65 to $61.15 per barrel, a rise of 2.77%. The March delivery Brent crude oil futures price rose by $1.60 to $65.47 per barrel, an increase of 2.51% [2] Policy and Regulatory Updates - The Ministry of Commerce of China announced the continuation of anti-dumping duties on imported solar-grade polysilicon from the U.S. and South Korea, effective from January 14, 2026, for a period of five years [2] - The Ministry of Industry and Information Technology issued an action plan for the high-quality development of industrial internet platforms from 2026 to 2028, aiming for significant progress in platform development and resource connectivity by 2028 [3][4] Company-Specific Developments - The approval of NVIDIA to export its H200 AI chips to China is expected to restart shipments to Chinese customers. This decision will be overseen by the U.S. Department of Commerce, which will also impose a fee of approximately 25% on the related transactions [7]

Core Viewpoint - The company has approved the use of idle funds for cash management, allowing for investments in low-risk financial products to enhance capital efficiency and shareholder returns [2][4][21]. Group 1: Board Meeting Overview - The sixth board meeting was held on January 13, 2026, with all nine directors present, confirming the legality and validity of the meeting [1][3]. - The board approved several resolutions, including the use of idle funds for cash management and the establishment of internal management systems [7][9]. Group 2: Use of Idle Funds - The company will use up to RMB 45 billion of idle self-owned funds for cash management, focusing on high-security, liquid low-risk investment products, valid for 12 months [2][14]. - The company will also use up to RMB 12 billion of temporarily idle raised funds for similar investments, ensuring that it does not affect ongoing projects [4][22]. Group 3: Investment Management - The investment strategy includes purchasing low-risk financial products with a maximum term of 12 months, ensuring liquidity and safety [14][26]. - The company will implement strict controls over the selection of investment products and will authorize the general manager to oversee the execution of these investments [15][28]. Group 4: Risk Management - The company acknowledges potential market risks due to macroeconomic factors but emphasizes that the investments are in low-risk categories [16][33]. - Risk control measures include regular monitoring of investment products and the establishment of a management system to ensure compliance with regulations [19][34]. Group 5: Impact on Company - The cash management strategy is designed to improve fund utilization efficiency without adversely affecting the company's operations or financial health [20][37]. - The company aims to maximize shareholder returns through prudent management of idle funds while ensuring compliance with relevant regulations [30][36].

Group 1 - The core focus is on developing new quality productivity in Suzhou High-tech Zone through strategic planning, innovation-driven approaches, and leveraging local industrial strengths [1][2] - Emphasis on the importance of foreign investment and the establishment of a robust service guarantee system for foreign enterprises to promote reinvestment and stimulate new quality productivity [2] - Highlighting the need for a collaborative innovation system involving enterprises, universities, and research institutions to enhance technological innovation as a core element of new quality productivity [2][3] Group 2 - The development of industrial parks is identified as a crucial vehicle for fostering new quality productivity, with a call to optimize service systems and strengthen resource support [2][3] - A focus on integrating AI with manufacturing to drive traditional industry upgrades, expand emerging industries, and cultivate future industries, aiming to build a modern industrial system [3] - The initiative includes enhancing the development of education and technology talent, promoting the transformation of scientific achievements into productive forces [3]

Core Viewpoint - The company has announced the continuation of cash management using idle raised funds, with a maximum amount of RMB 250 million, aimed at improving fund utilization efficiency while ensuring that it does not affect the construction and use of investment projects [1][9]. Investment Overview - **Investment Purpose**: The objective is to enhance the efficiency of fund utilization without impacting the construction of investment projects, thereby increasing returns for the company and its shareholders [3]. - **Investment Amount**: The total amount for the entrusted financial management is RMB 250 million [4]. - **Source of Funds**: The funds are sourced from temporarily idle raised funds [5]. Fundraising Background - The company was approved to publicly issue 40.2 million shares at a price of RMB 63.32 per share, raising a total of RMB 2545.464 million, with a net amount of RMB 2441.1345 million after deducting issuance costs [6]. Investment Types and Management - **Investment Type**: The company will invest in RMB structured deposits [7]. - **Investment Method**: The company will use temporarily idle raised funds to purchase cash management products issued by banks, which are characterized by high safety, good liquidity, and a maximum term of 12 months [8]. Recent Financial Management Situation - As of June 30, 2025, the company has invested RMB 2,081.956 million in projects funded by raised funds, with net interest income from the raised funds account amounting to RMB 7.2489 million [8]. Impact on the Company - The maximum amount of idle raised funds for cash management is RMB 250 million, which represents 12.11% of the company's latest cash balance, and is not expected to significantly impact the company's future operations, financial status, or cash flow [12].